What to Know About the 2025–2026 Respiratory Virus Season in the U.S.

Respiratory viruses are a fact of life each fall and winter in the United States. As we move through the 2025–2026 respiratory virus season, federal health agencies continue to emphasize a familiar message: vaccination, early testing, and timely treatment still matter—especially for people at higher risk.

Here’s what current guidance from the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) means for everyday readers.

The Big Three: Flu, COVID-19, and RSV

In the U.S., seasonal influenza (flu), COVID-19, and respiratory syncytial virus (RSV) are the main viruses driving hospitalizations during colder months. According to the CDC, these viruses tend to surge between late fall and early spring, though timing and severity vary year to year.

All three spread mainly through respiratory droplets and close contact. Symptoms often overlap:

Fever or chills
Cough
Sore throat
Runny or stuffy nose
Fatigue
Body aches

COVID-19 may also cause loss of taste or smell in some people, though this has become less common with newer variants. RSV is especially known for affecting infants and older adults and can lead to bronchiolitis or pneumonia.

Who Is at Higher Risk?

CDC guidance continues to highlight certain groups at higher risk of severe illness:

Adults age 65 and older
Infants and young children
Pregnant people
People with chronic conditions such as heart disease, lung disease, diabetes, or weakened immune systems
Residents of nursing homes or long-term care facilities

For these groups, prevention and early treatment are particularly important.

Vaccines: What’s Recommended

The CDC recommends updated seasonal flu vaccination for everyone 6 months and older, unless there is a specific medical reason not to receive it. Flu vaccines are reformulated each year to match circulating strains as closely as possible.

For COVID-19, the FDA has authorized and the CDC recommends updated vaccines designed to target more recently circulating variants. Protection from previous infection or vaccination can wane over time, and updated doses are intended to restore protection against severe disease and hospitalization.

RSV prevention has expanded in recent years. The CDC recommends:

A preventive RSV monoclonal antibody for eligible infants entering their first RSV season.
RSV vaccination for adults age 60 and older, based on shared decision-making with a clinician.
RSV vaccination during pregnancy (in specific timing windows) to help protect newborns.

These recommendations are based on randomized clinical trials that showed reduced risk of severe RSV illness in infants and older adults. As with any vaccine, side effects are usually mild—such as soreness at the injection site or fatigue—but rare adverse events are monitored through federal safety systems like FDA MedWatch.

Testing and Treatment: Don’t Wait if You’re High Risk

One important shift since early in the pandemic is the emphasis on early treatment.

For people at higher risk of complications:

Antiviral medications for flu (such as oseltamivir) work best when started within 48 hours of symptom onset.
Prescription antiviral treatments for COVID-19 are most effective when started early, typically within five days of symptoms.

These medications do not “cure” infection, but clinical trials have shown they can lower the risk of hospitalization and severe outcomes in high-risk patients.

If you test positive—or strongly suspect infection—and you’re in a high-risk category, contact a healthcare provider promptly.

What About Schools and Workplaces?

CDC guidance continues to emphasize practical prevention steps rather than widespread shutdowns. These include:

Staying home when sick
Improving indoor ventilation
Covering coughs and sneezes
Handwashing

Schools and employers may update policies based on local conditions, but broad nationwide restrictions are not currently part of standard seasonal guidance.

Health Equity and Access

Respiratory viruses do not affect all communities equally. Data from prior seasons show higher hospitalization rates among older adults, people with underlying conditions, and some racial and ethnic minority groups. Access to vaccination, paid sick leave, primary care, and early treatment all influence outcomes.

Vaccines are typically covered without cost-sharing by most private insurance plans, Medicare, and Medicaid. Uninsured individuals may have access through public health clinics or pharmacy programs, depending on local funding and eligibility rules. Checking with your state or county health department can clarify options.

Oral Health and Respiratory Illness

While brushing and flossing won’t prevent viral infections, maintaining good oral health can support overall well-being. For older adults in particular, poor oral hygiene has been associated with higher risk of secondary bacterial pneumonia in some studies. Dental care access remains an important part of whole-person health, especially for seniors and people with chronic disease.

What’s Still Uncertain?

Each season is different. Viral strains evolve, population immunity shifts, and hospitalization patterns can change. Surveillance data from the CDC help guide vaccine strain selection and treatment recommendations, but no vaccine is a perfect match every year.

Researchers continue to monitor:

How long protection from updated COVID-19 vaccines lasts
How RSV vaccines perform over multiple seasons
Whether new antiviral drugs improve outcomes

Guidance may evolve as new evidence emerges.

What This Means for Readers

For most healthy adults, respiratory virus infections are unpleasant but manageable. For older adults, infants, pregnant people, and those with chronic conditions, the risks are higher.

Practical steps still make a difference:

Stay up to date on recommended vaccines.
Test early if you have symptoms and are high risk.
Seek treatment promptly if eligible.
Stay home when sick to protect others.

These actions are not dramatic—but they remain the most evidence-based way to reduce severe illness during respiratory virus season in the United States.

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.

Sources

Centers for Disease Control and Prevention (CDC) – Seasonal Influenza, COVID-19, and RSV Guidance
U.S. Food and Drug Administration (FDA) – Vaccine Authorizations and Safety Monitoring
CDC MMWR – Respiratory Virus Surveillance Reports